J Korean Ophthalmol Soc > Volume 57(2); 2016 > Article
Journal of the Korean Ophthalmological Society 2016;57(2):243-247.
DOI: https://doi.org/10.3341/jkos.2016.57.2.243    Published online February 1, 2016.
Comparison of Short-Term Clinical Outcomes between Intravitreal Ranibizumab and Aflibercept in Retinal Angiomatous Proliferation.
Oh Jae Kim, Jae Hui Kim, Jong Woo Kim, Tae Gon Lee, Sung Won Cho, Dong Won Lee, Jung Il Han, Chul Gu Kim
Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea. chulgukim@kimeye.com
망막혈관종성증식에서 유리체강내 라니비주맙과 애플리버셉트 주입술의 단기 임상결과 비교
김오제⋅김재휘⋅김종우⋅이태곤⋅조성원⋅이동원⋅한정일⋅김철구
건양대학교 의과대학 김안과병원 안과학교실
Abstract
PURPOSE
To evaluate the 6-month outcomes of intravitreal ranibizumab and aflibercept treatment for patients with retinal angiomatous proliferation (RAP). METHODS: A retrospective review of medical records of 28 patients (31 eyes) diagnosed with RAP was performed. All patients were initially treated with 3 consecutive intravitreal ranibizumab or aflibercept injections after diagnosis. Additional treatment was performed when exudation recurred. The best-corrected visual acuity (BCVA) and central foveal thickness were measured before the first injection and 3 and 6 months after the first injection. The values measured before the treatment were compared with those after treatment. RESULTS: Sixteen eyes were treated with ranibizumab and 15 eyes with aflibercept. The logarithm of minimal angle of resolution (log MAR) values of BCVA before the first injection and 3 and 6 months after the first injection were 0.78 +/- 0.50, 0.47 +/- 0.30 and 0.59 +/- 0.41 in the ranibizumab group and 0.96 +/- 0.52, 0.83 +/- 0.52 and 0.74 +/- 0.56 in the aflibercept group, respectively. Central foveal thickness was 315.75 +/- 115.44, 188.38 +/- 57.33 and 218.50 +/- 96.49 microm in the ranibizumab group and 249.00 +/- 74.88, 143.73 +/- 32.73 and 196.73 +/- 94.08 microm in the aflibercept group, respectively. BCVA was significantly improved and central foveal thickness was significantly reduced at 6 months (p < 0.05) compared to measurements before the first injection in both groups. However, BCVA improvement and central foveal thickness were not significantly different between the 2 groups. CONCLUSIONS: Both intravitreal ranibizumab and aflibercept treatments were beneficial for both normalizing macular thickness and improving visual acuity in patients with RAP. The efficacy of the 2 drugs was not noticeably different.
Key Words: Aflibercept;Clinical outcomes;Ranibizumab;Retinal angiomatous proliferation


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2021 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next